An interventional study of Electro-Field Acupuncture and Electro-Acupuncture in Ischemic Stroke, Hemiplegia and Neurogenic Dysphagia, sponsored by National Hospital of Acupuncture, Vietnam. Not yet recruiting at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by National Hospital of Acupuncture, Vietnam · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing cerebrolysin in Ischemic Stroke — 5 open to participants now, 5 under way, none of them phase 3. cerebrolysin · Ischemic Stroke.
Among the 12 studies testing cerebrolysin in Ischemic Stroke, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2026, is one of 2 with no phase, and was the 12th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →5 of the 12 studies testing cerebrolysin in Ischemic Stroke are open now, in 4 countries. Recruiting first, the newest first:
Shaare Zedek Medical Center · Sites in Israel
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 18+
Hospital Universitario Dr. Jose E. Gonzalez · Sites in Mexico
Ages 18–80
Chang Gung Memorial Hospital
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 4
First in 2005; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 440 is above the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 92 across the 12 interventional studies. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with National Hospital of Acupuncture, Vietnam as lead sponsor.
National Hospital of Acupuncture, Vietnam has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing cerebrolysin in Ischemic Stroke, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objective: To assess the therapeutic efficacy of combined electroacupuncture (or electric field acupuncture), hydroacupuncture (Cerebrolysin or B-complex vitamins), and acupressure massage in restoring motor function and treating dysphagia in post-acute ischemic stroke patients, while evaluating safety profiles and prognostic factors associated with clinical outcomes.
Interventions:
Participants will be randomly assigned to one of four treatment arms:
Group 1: Electric field acupuncture + Cerebrolysin Acupoint injection + acupressure massage Group 2: Electric field acupuncture + B-complex vitamin Acupoint injection + acupressure massage Group 3: Electroacupuncture + Cerebrolysin Acupoint injection + acupressure massage Group 4: Electroacupuncture + B-complex vitamin Acupoint injection + acupressure massage The intervention duration is 30 days.
Inclusion Criteria: Patients were eligible for inclusion in the study if they met all of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Electro-Field Acupuncture · Device: Electro-Acupuncture · Drug: Cerebrolysin · Drug: B complex vitamin · Other: Acupressure Massage
Device: Electro-Field Acupuncture · Device: Electro-Acupuncture · Drug: Cerebrolysin · Drug: B complex vitamin · Other: Acupressure Massage
Electro-field acupuncture will be administered according to the standardized study procedure using predefined acupuncture points and electrical stimulation parameters.
Electro-acupuncture will be administered according to the standardized study procedure using predefined acupuncture points and electrical stimulation parameters.
Cerebrolysin will be administered by acupoint injection according to the standardized study protocol.
B complex vitamin will be administered by acupoint injection according to the standardized study protocol.
Acupressure massage will be administered as background therapy to all participants according to the standardized treatment protocol.
Change in Fugl-Meyer Assessment score for motor function in post-acute stroke patients
Motor function will be assessed using the Fugl-Meyer Assessment (FMA). The FMA motor function score ranges from 0 to 100, with higher scores indicating better motor function. The primary outcome is the change in FMA motor function score from baseline (Day 0) to Day 15 and Day 30.
Time frame: Baseline (Day 0) to Day 15 and Day 30
Change in Gugging Swallowing Screen (GUSS) score for swallow function in post-acute stroke patients
Dysphagia will be assessed using the Gugging Swallowing Screen (GUSS), a 24-item clinical swallowing assessment. The total GUSS score ranges from 0 to 20, with a maximum score of 20. Higher scores indicate better swallowing function and less severe dysphagia, while lower scores indicate greater swallowing impairment. The change in GUSS score from baseline to Day 15 and Day 30 will be evaluated.
Time frame: Baseline (Day 0) to Day 15 and Day 30
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — No. Individual participant data will not be shared outside the research team.
Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.
Of 573 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 18 months is below that.
Counting every sponsor, half of 654 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cerebrolysin